|
 |
Movement of New Cells Pave Way for Brain Research
(Source: University of Auckland) - Research from The University of Auckland, alongside colleagues in Sweden, has identified how stem cells move from the site of generation to areas affected by neurological diseases.
Financial Matters: What to Expect
(Source: Bend Weekly) - A Bend Weekly reader wrote to Professor Michael Myers, asking, "My husband's Alzheimer's condition has reached a stage where I can no longer manage him. Soon I will have to take him to a nursing home. What can I expect? What will happen to me financially?"
Harnessing Brain's Plasticity Key to Treating Neurological Damage
(Source: University of California) - In the last forty years, simple neural prostheses have been developed to treat loss of hearing, bladder control and respiration. Recent advances have also led to the development of "smart" neural prostheses, which engage higher levels of brain function.
Scrapbooks Help Preserve Memories
(Source: West Central Tribune) - The pages of scrapbooks at Pleasant View Nursing Home in Wilmar, MN, capture a wealth of memories for residents: birthdays, Halloween parties and special events.
Coprexa Awarded Grant for Preclinical Testing
(Source: Market Wire) - Pipex Pharmaceuticals announced that its lead anti-copper drug candidate, Coprexa™, has been awarded a grant from the National Institutes of Health to support testing of the drug for the treatment for Alzheimer's disease. The grant was for $306,172.
Protein Inhibitor Tangles with Alzheimer's Disease
(Source: EurekAlert!) - Using laboratory mice, Mayo Clinic researchers have shown that a drug which inhibits the protein Hsp90 reduces brain levels of the protein tau, the abnormal accumulation of which has been implicated in the pathogenesis of Alzheimer's disease.
Agitation in the Elderly
(Source: Psychiatric Times) - As many as 50% of patients with dementia will exhibit agitation, including aggression, combativeness, shouting, hyperactivity and disinhibition.
A Treatment for Mild-to-Moderate Parkinsonian Dementia
(Source: Pharma Live) - For the first time, people suffering from Parkinson's dementia have a treatment option. The U.S. Food and Drug Administration recently approved Exelon® (rivastigmine tartrate) for the treatment of mild-to-moderate Parkinson's dementia, making it the first and only medication available for the treatment of this condition. Exelon is also approved for the treatment of mild-to-moderate Alzheimer's disease.
|
|